Cemsidomide Drug Asset Due Diligence Report 2026

This Cemsidomide Drug Asset Due Diligence Report was built with PatSnap Life Sciences MCP workflows. Drug & Asset MCP establishes identity, ownership and stage; Clinical Trials MCP checks design, endpoints and readouts; Company & Deal Intelligence MCP reconstructs transaction precedent. Explore the MCP servers used in this report.

Decision date: 16 September 2026. Currency fields are presented in US$ millions as returned by the deal dataset. This is a screening memorandum, not legal, medical, patent or investment advice.

Phase 2

Highest phase

Registered trials

Result records

Matched deals

Executive recommendation: CONDITIONAL GO

Decision memo

Advance with milestone-based economics while efficacy durability, safety differentiation, patent scope, and market positioning are validated.

The central underwriting question is whether Cemsidomide can convert its Degradable Molecular Glue profile and IKZF1 x IKZF3 biology into clinically meaningful differentiation while preserving an investable safety, IP and commercial position.

1. Asset identity and development status

Asset	Cemsidomide (query alias: Cemsidomide)
Modality / target	Degradable Molecular Glue; IKZF1 x IKZF3; IKZF1 degraders, IKZF3 degraders, Proteolysis
Highest global status	Phase 2
Originator	C4 Therapeutics, Inc.
Active developers	C4 Therapeutics, Inc.

The MCP disease footprint includes Multiple Myeloma. The highest-phase flag is a useful orientation point, but the licensing case depends on indication-level evidence and rights, not the global label alone.

2. Clinical program: design and endpoint audit

Registry	Phase	Status	Enrollment	Lead primary endpoint
NCT07284758	Phase 2	Recruiting	100	Primary endpoint not disclosed in English source
NCT07280013	Phase 1	Recruiting	60	Primary endpoint not disclosed in English source
NCT04756726	Phase 1	Active, not recruiting	224	Primary endpoint not disclosed in English source

The trial set should be diligenced for randomization, comparator relevance, endpoint hierarchy, analysis population, multiplicity, geographic mix and readout timing. For early-stage studies, safety and dose selection can be as decision-critical as response rate.

Reproduce the asset-to-trial workflow with PatSnap MCP

3. Clinical readouts: what is known

UPDATED RESULTS OF A PHASE 1 FIRST-IN-HUMAN STUDY OF CEMSIDOMIDE, A NOVEL MONODAC® DEGRADER, WITH DEXAMETHASONE (DEX) IN PATIENTS WITH (RRMM)

Phase 1; n=73; evaluation: Positive. Reported fields: AE(discontinuation) = 4.0 Pts ; ORR = 40.0 %

MOMENTUM: A PHASE 2, OPEN-LABEL, SINGLE-ARM, MULTICENTER STUDY TO EVALUATE THE EFFICACY OF CEMSIDOMIDE + DEXAMETHASONE IN SUBJECTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA

Phase 2; n=100; evaluation: Positive. Reported fields: AE(Grade 5) = 1.0 %

Updated Results of a Phase 1 First-in-Human Study of Cemsidomide (CFT7455), a Novel MonoDAC® Degrader, with Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma (RRMM)

Phase 1/2; n=64; evaluation: Positive. Reported fields: ORR = 40 % ; ORR = 50 %

These fields are structured evidence signals, not a substitute for statistical review. The next diligence pass should reconcile denominators, confidence intervals, follow-up, censoring, dose cohorts and treatment-emergent toxicity against the original abstract, registry and protocol.

4. Market and competitive position

Cemsidomide addresses Multiple Myeloma. Commercial attractiveness rests on addressable patients, treatment-line placement, duration, administration burden, pricing and displacement of entrenched standards. The modality—Degradable Molecular Glue—must demonstrate a benefit large enough to offset class-specific safety and operational costs.

The MCP screen returned 6 matched transaction record(s) under the scope “target-level comparable: IKZF1 x IKZF3.” Partner activity is a market-validation signal, but it does not establish net present value.

5. Transaction precedent and economics

Transaction-scope note: No direct asset-specific transaction was returned. The table below shows target-level comparable: IKZF1 x IKZF3 records as comparable precedents only.

Date	Transaction	Phase at deal	Disclosed economics
2025-06-24	Starton, Bend team on proprietary oral sustained-release dosage form of lenalidomide	Approved	Financial terms not disclosed
2025-05-06	Transaction title not available in English source	Preclinical	US$8.5M stated total
2022-12-12	Preclinical Data from Kymera Therapeutics’ Collaborations Demonstrate Therapeutic Potential of STAT3 Degraders in CTCL and IRAKIMiD Combination with BCL-2 Inhibitor in MYD88-Mutant DLBCL at the American Society of Hematology Annual Meeting	Phase 1	Financial terms not disclosed

Headline values are not directly comparable. Diligence should normalize upfront cash, equity, development and sales milestones, tiered royalties, opt-in mechanics, cost sharing, change-of-control clauses and geography.

6. IP and freedom-to-operate screen

The milestone feed surfaced a patent-application signal described as “Methods and materials for treating cancer”. The milestone feed surfaced a patent-application signal described as “Morphic forms of CFT7455 and methods of manufacture thereof”. The milestone feed surfaced a patent-application signal described as “Crystal form of CFT7455 and method for producing same”.

The claim chart should separately test composition or sequence coverage, formulation and dosing, indication and biomarker claims, combinations, manufacturing know-how, prosecution history, term extensions and third-party blocking rights.

7. Principal risks and diligence gates

Clinical differentiation versus current standards and pipeline competitors
Safety, dose optimization, and long-term tolerability
Patent scope, territorial rights, manufacturing, and commercial positioning

Cross-functional diligence should also test CMC comparability, supply chain, pharmacovigilance, regulatory correspondence, data integrity, investigator concentration, partner obligations and change-of-control restrictions.

8. Final go/no-go memorandum

CONDITIONAL GO